A rifamycin derivative, rifampin, has been found to inhibit bacterial RNA synthesis (3, 12) . This antibiotic blocks RNA chain initiation after binding of the bacterial RNA polymerase to DNA.
Rifampin also inhibits the growth of vaccinia virus at a late stage of its replicative cycle (4, 11) . The sensitive step is not yet completely identified (6, 10) ; however, the mechanisms with which rifampin blocks viral and bacterial multiplication may not be identical.
We have previously shown that rifampin reversibly inhibits the intracellular replication of a mutant vesicular stomatitis virus (VSV) strain (9) . In this report, we will study the mechanisms of this inhibition.
MATERIALS AND METHODS
Cell cultures. Mouse L cells, African green monkey cells (line BSC) and chicken embryo fibroblasts (CEF) were grown in Eagle medium (MEM) 0111 supplemented with tryptose phosphate broth (2.95 g/liter) and 10% heat-inactivated calf serum.
Viruses. The Indiana strain of VSV was grown in L cells. A large plaque mutant of VSV obtained in this laboratory was employed. Cells were infected with 10-l PFU per cell in Eagle medium without calf serum. The virus produced was harvested after 24 h of incubation at 37 C. Infectivity assays were performed by routine plaque titration.
Rifampin-resistant mutants were selected by 4 to 6 successive plaque purifications of virus grown in the presence of rifampin at a concentration of 100 #g of medium per ml.
VSV virions were concentrated by precipitation with polyethylene glycol 6000 and purified using a DEAE-cellulose column chromatography, as described by McSharry and Wagner (8) .
Antibiotics. Rifampin was supplied by Lancini Lepetit Spa Milan (Italy) through the courtesy of S.
Furesz. Prior to use, the drug was dissolved in phosphate broth (PBS) buffer and diluted in MEM medium to a suitable concentration.
Actinomycin D (a gift of Merck Sharp and Dohme Research Laboratories, Rahway, N. J.) was dissolved in a 5% ethanol PBS buffer at a concentration of 1 mg/ml and diluted with medium.
Determination of total viral RNA synthesis. A monolayer of L cells, grown in plastic petri dishes (35 by 10 mm), was infected with VSV at a multiplicity of 10 PFU/cell. After an adsorption period of 1 h at 37 C, rifampin (200 jAg/ml), actinomycin D (2 ug/ml), and [5-'H] uridine (21 Ci/mM; 2 MCi/ml) were added to the infected cells.
The cells were harvested at hourly intervals. Cumulative incorporation of radioactive uridine into trichloroacetic acid-precipitable fraction was assayed in a Packard Tri-Carh liquid scintillation counter.
[5-'Hluridine (21 Ci/mM) was purchased at the Centre de l'Energie Atomique (C.E.A.) Saclay (France).
VSV-transcriptase assay. The enzyme was assayed according to the technique described by Baltimore, Huang, and Stampfer (1) . In our assays the tests were performed at 32 C and pH 7.2. Amounts of viral protein ranging from 10 to 40 sg were determined by the method of Lowry (7) and added to the reaction mixture.
As a tracer, ['H]GTP (0.25 mCi/0.027 mg), purchased at C.E.A. Saclay (France), was employed.
RESULTS
The VSV strain sensitive to rifampin was a large plaque mutant of the Indiana strain. However, during the passages, small or large plaque mutants were obtained. There was no correlation between the size of the plaque and the sensitivity of the virus to the antibiotic.
The inhibitory effect of rifampin on VSV replication was independent of the cell system used. In parallel sets of preparations, this antibiotic at the same concentration did not affect the replication of encephalomyocarditis virus (EMC) in L cells or of poliovirus in BSC cells ( Table 1) .
The rate of inhibition was proportional to the concentration of rifampin used ( Fig. 1) Table 2) .
Effect of rifampin during the first replicative cycle. VSV sensitive to rifampin (VSV-RIF+) or resistant to it (VSV-RIF-) were measured by yield inhibition in the presence of the drug. Viral yields were titered every hour during the first replicative cycle (10 h). A significant difference between treated and untreated virus appeared with VSV-RIF+: 5 to 7 h after infection the inhibition was about 30-fold ( Fig. 2A) . The multiplication of VSV-RIF-was unaffected by rifampin (Fig. 2B) .
In further experiments we investigated the mechanisms of the antiviral effect of rifampin.
Viral RNA synthesis in the presence of rifampin. In uninfected cells treated with rifampin, no significant change in the cumulative incorporation of [5-3H] (Fig. 3) .
Sequential addition of rifampin. Rifampin was added at hourly intervals during the first VSV replicative cycle. Viral yields were titered 11 h after the infection of cells. The inhibition of VSV multiplication was maximal when the drug was added 1 h after infection and decreased rapidly (Fig. 4) . A possible effect of rifampin on VSV transcription was, therefore, studied in the following experiments. Ne.s.bstkfo..*. Inhibition of VSV transcriptase activity by rifampin. Transcriptase activity was tested in vitro with purified virus. In the first experiment, rifampin was added to the reaction mixture at the beginning of incubation ( Table 3) RIF+ mutant or of a subclone selected from this population was greatly inhibited.
In the second experiment, the kinetics of incorporation of [3H]GMP was examined when rifampin (4 jig) was added at different time intervals to the reaction mixture. VSV-RIF+ was incubated with the components of the reaction assay at 32 C for 100 min (Fig. 5) . The transcriptase activity was inhibited when rifampin was added 10 Rifampin (100 Ag/ml) was added at hourly intervals.
Plaque titrations were performed after 11 h of infection. 
DISCUSSION
Rifampin reversibly inhibits the intracellular replication of a VSV mutant. The experimental data presented here show that the drug decreases the rate of total viral RNA synthesis in the cells and inhibits viral transcriptase activity when assayed in a cell-free system. Some rifampin derivatives known to inhibit reverse transcriptase activity of oncornaviruses similarly inhibit VSV transcriptase (5). For VSV-RIF+, the mutation might be situated at the transcriptase level and could perhaps explain the affinity of the enzyme for rifampin.
In summary, our studies seem to indicate that in the case of the mutant VSV strain, the primary change which causes rifampin sensitivity might be located at the transcription level. This observation does not exclude, however, the possibility that this drug might have a different effect on other viruses. Events in the maturation of vaccinia virus (6, 10) , as well as poliovirus in suspended cell cultures (2), could also be involved. In the case of VSV, this problem will be further investigated using different VSV strains grown in other cell systems. ACKNOWLEDGMENTS I thank Charles Chany and Carol Girard for their helpful suggestions during the course of these experiments and the preparation of the manuscript, and I acknowledge the excellent technical assistance of Mireille Robert.
